Companies › Syndax Pharmaceuticals
2 active drug programs in 13 registered trials: 8 Phase 1, 3 Phase 2, 2 Phase 3; Respiratory, Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| revumenib Menin/Histone-lysine N-methyltransferase MLL inhibitor; Menin inhibitor | MEN1, KMT2A | Phase 3 | Acute Myeloid Leukemias; Acute Myeloid Leukemia; Acute Myeloid Leukemia, Adult; Recurrent Acute Leukemia of Ambiguous Lineage … | Feb 2027 |
| Axatilimab Macrophage colony stimulating factor receptor inhibitor | CSF1R | Phase 2 | Idiopathic Pulmonary Fibrosis; Chronic Graft-versus-host-disease | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06132256 | Axatilimab | Phase 2 | Idiopathic Pulmonary Fibrosis | Respiratory | Nov 2026 |
| NCT06177067 | revumenib | Phase 1 | Refractory Acute Myeloid Leukemia | Oncology | Jan 2027 |
| NCT06222580 | revumenib | Phase 1 | Acute Myeloid Leukemia With FLT3/ITD Mutation | Oncology | Jan 2027 |
| NCT06226571 | revumenib | Phase 1 | Acute Myeloid Leukemias | Oncology | Feb 2027 |
| NCT06313437 | revumenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Mar 2027 |
| NCT04710576 | Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | Respiratory | Sep 2027 |
| NCT04065399 | revumenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT05761171 | revumenib | Phase 2 | Recurrent Acute Leukemia of Ambiguous Lineage | Oncology | Dec 2027 |
| NCT05886049 | revumenib | Phase 1 | Acute Myeloid Leukemia | Oncology | Dec 2027 |
| NCT06575296 | revumenib | Phase 1 | Acute Leukemia | Oncology | Apr 2028 |
| NCT07356154 | revumenib | Phase 1 | Leukemia | Oncology | Jan 2029 |
| NCT07211958 | revumenib | Phase 3 | Acute Myeloid Leukemias | Oncology | Jun 2029 |
| NCT06652438 | revumenib | Phase 3 | Acute Myeloid Leukemia, Adult | Oncology | Dec 2029 |
Cash and short-term investments of $427m on 2026-09-30; operating cash outflow about $145m a year; runway about 35 months at that burn, to Sep 2029; 4 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
MiNK Therapeutics SPARK Biopharma NuvOx Olema Pharmaceuticals Celldex Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.